Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | HMGCR | P04035 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | GCGR | P47871 | 8/20 | 0.47 |
| ▸ | AR | P10275 | 8/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9261550 | 1.00 | ESR1 (0.50) | ESR1HMGCRCHRM1TBXA2RPDE4A | |
| SCHEMBL6958682 | 0.90 | AR (0.53) | ESR1HMGCRCHRM1TBXA2RPDE4A | |
| SCHEMBL8846069 | 0.85 | GCGR (0.50) | ESR1HMGCRCHRM1TBXA2RPDE4A | |
| SCHEMBL7561153 | 0.85 | ESR1 (0.62) | ESR1HMGCRCHRM1TBXA2RPDE4A | |
| SCHEMBL8973684 | 0.85 | ESR1 (0.62) | ESR1HMGCRCHRM1TBXA2RPDE4A | |
| SCHEMBL9270541 | 0.80 | HMGCR (0.62) | ESR1HMGCRCHRM1TBXA2RPDE4A | |
| SCHEMBL9270549 | 0.80 | HMGCR (0.62) | ESR1HMGCRCHRM1TBXA2RPDE4A | |
| SCHEMBL8949683 | 0.80 | GCGR (0.53) | ESR1HMGCRCHRM1TBXA2RPDE4A | |
| SCHEMBL15329710 | 0.80 | ESR1 (0.48) | ESR1HMGCRCHRM1TBXA2RPDE4A | |
| SCHEMBL6954644 | 0.80 | ESR1 (0.48) | ESR1HMGCRCHRM1TBXA2RPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0325130-B1 | Substituted pyridines | BAYER AG (DE) | 2003-11-05 | — | — | EP | disclosed |
| EP-1123924-A1 | Substituted pyridines as HMG-COA reductase inhibitors | BAYER AG (DE) | 2001-08-16 | — | — | EP | disclosed |
| EP-1123925-A1 | Process for preparation of substituted pyridines | BAYER AG (DE) | 2001-08-16 | — | — | EP | disclosed |
| CN-1274719-A | Process for preparation of substituted pyridine compound | BAYER AG (DE) | 2000-11-29 | — | — | CN | disclosed |
| CN-1055684-C | Process for preparing substituted pyridine compounds | BAYER AG (DE) | 2000-08-23 | — | — | CN | disclosed |
| US-5401746-A | FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND HMG-COA REDUCTASE | BAYER AKTIENGESELLSCHAFT (DE) | 1995-03-28 | — | — | US | disclosed |
| US-5169857-A | Anticholesterol agents | BAYER AKTIENGESELLSCHAFT (DE) | 1992-12-08 | — | — | US | disclosed |
| US-5006530-A | Certain 7-[2,6-diisopropyl-4-phenyl-5-lower alkoxymethyl-pyrid-3-yl]-3,5-dihydroxy-6-enoates and derivatives useful for treating circulatory diseases | BAYER AKTIENGESELLSCHAFT (DE) | 1991-04-09 | — | — | US | disclosed |
| EP-0325130-A2 | Substituted pyridines | BAYER AG (DE) | 1989-07-26 | — | — | EP | disclosed |